ArticleIn vivo (Athens, Greece)
Pain Associated With Head and Neck Cancer Photoimmunotherapy.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimHead and neck photoimmunotherapy (HN-PIT) achieves local control in unresectable locally advanced or recurrent head and neck cancer; however, acute post-treatment pain remains clinically important. This retrospective study evaluated pain timing and intensity, the association between a revised analgesic protocol and pain, the relationship between tumor diameter and pain, and adverse events after HN-PIT. PATIENTS AND
methodsPatients who underwent HN-PIT at Tokyo Medical University Hospital between February 2021 and November 2025 were reviewed. Pain outcomes were analyzed in 47 patients during the first HN-PIT cycle; adverse events were evaluated in 48 patients, including one excluded from pain assessment because of intubation. Numerical Rating Scale (NRS) scores were recorded from illumination day to day 7, with the highest score defined as maximum NRS. Maximum NRS scores were compared between 2021-2023 and 2024-2025, before and after implementation of a multimodal analgesic protocol. Pearson's correlation coefficient and simple linear regression assessed the relationship between maximum tumor diameter and maximum NRS. Adverse events were graded according to CTCAE v5.0.
resultsAmong 45 patients who experienced pain during the first week, 28 (62%) had peak NRS scores on illumination day. Maximum NRS was lower in 2024-2025 than in 2021-2023 (5.17±3.16
conclusionPain after HN-PIT peaked on illumination day. A standardized multimodal analgesic protocol was associated with reduced pain intensity. Tumor diameter was not a major pain severity determinant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.